Law Offices of Howard G. Smith reminds investors that all purchasers of the common stock of Immunomedics, Inc. (“Immunomedics” or the “Company”) (NASDAQ:IMMU) between May 9, 2013 and October 9, 2013, inclusive (the “Class Period”), have until April 28, 2014, to file a motion to be appointed as lead plaintiff in the shareholder lawsuit.

Immunomedics is a biopharmaceutical company focused on the development of monoclonal antibody-based products for targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s product Veltuzumab is a humanized anti-CD20 antibody for the treatment of all non-cancer indications. In July 2008, Immunomedics entered into a license and collaboration agreement with Nycomed GmbH to develop, manufacture and commercialize Veltuzumab. Nycomed was acquired by Takeda Pharmaceutical Company in September 2011.

The Complaint alleges that during the Class Period defendants issued materially misleading statements concerning Veltuzumab and its related development by Takeda-Nycomed, but failed to disclose to investors that, prior to and during the Class Period, the Company and Takeda-Nycomed were embroiled in an ongoing dispute concerning a delay in Veltuzumab’s development.

On October 9, 2013, in a Form 8-K filed with the Securities and Exchange Commission, Immunomedics disclosed that the Company’s agreement with Nycomed to develop, manufacture and commercialize Veltuzumab has been terminated. According to the Form 8-K, Immunomedics previously notified Nycomed of its concern about delays in the product's advancement, and on May 14, 2013, notified Nycomed that Nycomed was in material breach of the agreement and that the agreement would terminate if the breaches remained uncured. On October 9, 2013, Immunomedics announced that the agreement had been terminated.

If you purchased Immunomedics common stock during the Class Period, you may move the Court no later than April 28, 2014, to serve as lead plaintiff, if you meet certain legal requirements. To be a member of the Class, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.